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httpManagement of the left subclavian artery and
neurologic complications after thoracic
endovascular aortic repair
Benjamin O. Patterson, PhD, MRCS,a Peter J. Holt, PhD, FRCS,a Christoph Nienaber, MD,b
Ronald M. Fairman, MD,c Robin H. Heijmen, MD, PhD,d and Matt M. Thompson, MD, FRCS,a
London, United Kingdom; Rostock, Germany; Philadelphia, Pa; and Nieuwegein, The Netherlands
Objective: Thoracic endovascular aortic repair (TEVAR) of various pathologies has been associated with peri-
interventional neurologic complication rates of up to 15%. The objective of this study was to determine the inﬂuence
of the management of the left subclavian artery (LSA) on neurologic complications and to deﬁne subgroups that might
beneﬁt from LSA revascularization.
Methods: The Medtronic Thoracic Endovascular Registry (MOTHER; Medtronic, Santa Rosa, Calif), consists of data from
ﬁve sponsored trials and one institutional series incorporating 1010 patients undergoing TEVAR from 2002 to 2010. Peri-
operative stroke and spinal cord injury (SCI) rates were described according to the management of the LSA and presenting
pathology. Multivariate analysis was performed to determine factors associated with perioperative neurologic complications.
Results:Of 1002 patients included in the analysis, stroke occurred in 48 (4.8%), and SCI developed in 42 (4.2%)#30 days
of surgery. The stroke rate was 2.2% in patients with no coverage of the LSA vs 9.1% with coverage alone and 5.1% in
patients who underwent LSA revascularization before coverage (P < .001). This relationship was strongest in the
aneurysm group. Coverage of the LSA without revascularization was independently associated with stroke (odds ratio
[OR], 3.5; 95% conﬁdence interval [CI], 1.7-7.1), speciﬁcally in the posterior territory (OR, 11.7; 95% CI, 2.5-54.6), as
was previous cerebrovascular accident (OR, 7.1; 95% CI, 2.2-23.1; P[ .001), whereas a covered LSA was not associated
with an increased risk of SCI.
Conclusions: Coverage of the LSA without revascularization is an important modiﬁable risk factor for stroke in patients
undergoing TEVAR for a thoracic aortic aneurysm. Prior revascularization appears to protect against posterior circu-
lation territory stroke. (J Vasc Surg 2014;60:1491-8.)Endovascular surgery is now the treatment of choice
for much of the pathology of the descending thoracic
aorta. The early mortality beneﬁts observed compared
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://dx.doi.org/10.1016/j.jvs.2014.08.114of some elements of the operative technique is required
to reduce the incidence of serious morbidity.1,2
Coverage of the left subclavian artery (LSA) is often neces-
sary to establish an adequate landing zone in patients under-
going thoracic endovascular aortic repair (TEVAR. Not
revascularizing the LSA was previously considered safe, but
as further data have emerged, there have been concerns that
reduction of ﬂow through the left vertebral arterymay increase
the risk of postoperative stroke and spinal cord ischemia.3-6
Guidelines forpracticehavebeen recommendedby theSociety
for Vascular Surgery (SVS), but it has been acknowledged that
these were based on poor-quality literature.7
An adequately powered study is required to deﬁne
whether coverage of the LSA confers an additional risk of
neurologic complication. Deﬁning any subgroups of
patients who would derive beneﬁt from selective LSA
revascularization is important from a clinical perspective.
This report from the Medtronic Thoracic Endovascular
Registry (MOTHER; Medtronic, Santa Rosa, Calif)
database describes how the management of the LSA may
inﬂuence neurologic events after TEVAR and gives some
insight into the etiology of these complications.
METHODS
Trials. The MOTHER registry contains the data from
ﬁve prospective trials combined with institutional data from
one center, St George’s Vascular Institute (SGVI). The1491
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phase II/III VALORI (Evaluationof theMedtronicVascular
Talent Thoracic Stent Graft System for the Treatment of
Thoracic Aortic Aneurysms),8 the intervention arm of the
INSTEAD (Investigation of Stent Grafts in Aortic Dissec-
tion)9 randomized control trial, and three phase IV trials
(VALOR II,10 Assessment of the Captivia Delivery System
for Use With the Valiant Stent Graft [CAPTIVIA],11
and VALIANT Thoracic Stent Graft Evaluation for
the Treatment of Descending Thoracic Aortic Dissections
[VIRTUE]12). The institutional data included all TEVAR
procedures performed during a 10-year period that used the
Talent orValiant stent graft systems thatwere not entered into
anyof the registries.The registry has beenpreviously described
in detail.13 All trials were registered with full Institutional
Review Board approval. Prospective consent was not deemed
necessary for the SGVI institutional series because it was
classed as quality improvement rather than as a clinical trial.
Immediate postinterventional events were documented
with particular emphasis on mortality, stroke (which
included any transient neurologic events), and evidence of
acute spinal cord injury (SCI). For the industry-sponsored
trials, each event was discussed by an independent adjudica-
tion panel and necessary imaging obtained. For the SGVI se-
ries, examination by a stroke physician took place wherever
stroke or SCI was suspected, and the relevant imaging was
reviewed. Type of stroke, evidence of resolution, and fatal
outcome were deﬁned, and where possible, information
regarding the vascular territory of each stroke was recorded.
This was categorized as posterior circulation (ie, vertebral ar-
tery territory), anterior circulation (carotid artery), hemor-
rhagic, multiple (more than one) territories, or unknown.
The occurrence of paraparesis and paraplegia was docu-
mented, and the degree of recovery was deﬁned. Data
regarding the management of the LSA were collected pro-
spectively in each series, and patients were assigned to one
of three groups: those with the LSA uncovered (Ishimaru
zone 3-4), those in which the LSA was covered and not
revascularized, or those patients in whom the LSA was
covered and revascularized before or at the time of TEVAR.
All of the studies relied on the discretion of the oper-
ating surgeon to determine if LSA revascularization or
any further debranching were required based on local pro-
tocols and preoperative imaging. The SGVI patients all un-
derwent duplex and computed tomography (CT) imaging
of the carotid and vertebral arteries in conjunction with
detailed clinical assessment to determine if revasculariza-
tion was deemed to be beneﬁcial. Patients with zone 0 pa-
thology that required complete debranching were
excluded. The database did not include patients who un-
derwent LSA revascularization as part of a staged proce-
dure but did not undergo TEVAR. All patients with
zone 1 coverage underwent carotid-to-carotid crossover
bypass. No endovascular revascularization procedures (ie,
chimney grafts) were described in the series.
Statistical analysis. Data from each source were
pooled and analyzed using SPSS 20 software (IBM,
Armonk, NY). The preoperative characteristics of eachgroup were examined using the analysis of variance test
for variance for continuous variables and the Fisher exact
test or the c2 test for categoric variables. A univariate anal-
ysis for the strength of association of different methods of
managing the LSA with adverse events #30 days was per-
formed using the Fisher exact test or the c2 test where con-
tingency tables were larger than 2  2.
The linear-by-linear association statistic was used for
numeric ordinal variables. Odds ratios (ORs) were quanti-
ﬁed along with 95% conﬁdence intervals (CIs). The differ-
ence in the incidence of postoperative 30-day outcomes
among the various LSA management groups was tested us-
ing the Fisher exact test, and ORs were calculated. Those
variables (identiﬁed on univariate analysis) with a P value
of <.1 were entered into a binary logistic regression model
that incorporated backward variable selection to model the
30-day incidence of stroke and SCI. The Wald test for sig-
niﬁcance was performed at each step to determine the
contribution of the each variable to the model based on
the OR and 95% CI. The OR is the change increase in
the odds of an event given a 1-point change in the value
of a predictor, which has implications for the interpretation
of continuous variables; for example, the OR for age repre-
sents an increase or decrease in relative risk per year.
RESULTS
Demographics. The MOTHER database comprised
1010 patients who underwent TEVAR, of whom 1002
had sufﬁcient data regarding the management of the LSA
to be included in the present analysis. Of these patients,
971 were treated for thoracic aortic aneurysms (TAAs) or
aortic dissection and 31 for various other pathologies
such as traumatic injury, intramural hematoma, or pene-
trating ulcer. In 537 patients the LSA was not covered,
in 322 the LSA was covered and not revascularized, and
143 underwent prior or simultaneous revascularization
procedures of the LSA. The demographics of the patients
grouped by management of the LSA are reported in
Table I. The exact revascularization procedure performed
varied according to local protocol but was a bypass or
transposition in all cases.
The prevalence of comorbidities was slightly higher in
patients who did not require LSA coverage, in particular
renal impairment, diabetes, chronic obstructive pulmonary
disease, cerebrovascular disease, and peripheral vascular dis-
ease. More emergency procedures were performed in the
patients who underwent LSA coverage (26.4% not revascu-
larized and 20.9% revascularized) compared with those that
did not (11.4%). A higher proportion of patients were at
American Society of Anesthesiologists Physical Status Clas-
siﬁcation 4 in the group with LSA coverage (with and
without revascularization). The LSA was covered without
revascularization most frequently during treatment for
acute type B aortic dissection and covered with revascular-
ization most often in cases of chronic type B dissection. Of
the 143 patients who had LSA revascularization, 12 under-
went complete aortic debranching via sternotomy and were
not included in the descriptive analysis.
Table I. Demographics of patients who underwent different management for the left subclavian artery (LSA)
Variablesa LSA not covered (n ¼ 537)
LSA covered
PbNot revascularized (n ¼ 322) Revascularized (n ¼ 143)
Males 330 (61.5) 231 (71.7) 102 (71.3) .003
Mean age (range), years 70.9 (15-89) 67 (25-94) 65.8 (27-87) <.001
Pathology
Aneurysm 394 (73.4) 185 (57.5) 86 (60.1) <.001
Chronic type B 96 (17.8) 60 (18.6) 38 (26.6) <.001
Acute type B 38 (7.1) 61 (18.9) 15 (10.4) <.001
Comorbidityc
Previous AAA 121 (22.5) 57 (17.7) 30 (21) <.001
Renal impairment 97 (18.1) 51 (15.8) 14 (9.8) .089
Hypertension 438 (83.7) 249 (77.3) 100 (75.8) .080
Diabetes 83 (15.5) 41 (12.7) 13 (9.8) .170
COPD 163 (30.4) 75 (23.3) 23 (16.1) .003
Cerebrovascular disease 72 (13.6) 40 (12.9) 14 (9.8) .066
Smoking history 350 (67.7) 196 (64.7) 83 (63.4) .552
Cardiac disease 89 (17.2) 40 (12.4) 20 (17.4) .012
Peripheral vascular disease 85 (20) 37 (11.5) 11 (11.3) .117
Hyperlipidemia 244 (52.2) 92 (43.8) 52 (49.5) .127
Medications
ACE inhibitor 162 (46.2) 77 (44) 22 (34.4) .218
ß-Blocker 226 (63.3) 105 (60) 35 (53) .254
Calcium channel blocker 115 (38.1) 50 (15.5) 23 (38.3) .368
Statins 162 (52.6) 78 (49.4) 35 (55.6) .670
Nonelective 61 (11.4) 85 (26.4) 29 (20.9) <.001
Devices used, No. (SD) 2.23 (1.16) 2.36 (1.4) 2.3 (1.4) .409
ASA classiﬁcation
1 26 (5.3) 20 (6.7) 6 (4.6) .133
2 93 (18.8) 76 (25.3) 26 (20)
3 248 (50.1) 139 (46.3) 61 (46.9)
4 114 (23) 59 (19.7) 37 (28.5)
5 14 (2.8) 6 (2) 0
Missing 42 (7.8) 22 (6.8) 13 (9.1)
Ishimaru landing zone
0 0 4 (1.2) 8 (5.6) <.001
1 0 35 (10.9) 27 (19)
2 0 282 (87.9) 107 (75.3)
3 364 (67.9) 0 0
4 172 (32.1) 0 0
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; SD,
standard deviation.
aCategoric data are given as absolute numbers (%), and continuous variables are shown as indicated.
bStatistical analysis used analysis of variance and the c2 test for difference in continuous and categoric variables respectively.
cComorbidities were assessed as: renal impairmentdestimated glomerular ﬁltration rate <60 mL/min/1.73 m2; hypertensiondtreated hypertension or blood
pressure >140/90 mm Hg; cerebrovascular diseasedprevious stroke or transient ischemic attack reported by patient or in medical records; cardiac
diseasedischemic heart disease or other structural or functional cardiac problem; hyperlipidemiadtaking antilipid medication or an abnormal lipid proﬁle;
smoking historydprevious or current smoker.
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ﬁrst 30 days after surgery, there were more strokes in all
territories in those patients whose LSA was covered,
regardless of revascularization status (Table II). The rate
of posterior territory strokes was higher in the patients
whose LSA was covered and not revascularized compared
with those whose LSA was revascularized (3.8% vs 0.7%;
Fig 1). The rate of anterior circulation strokes was similar in
the two groups (2.8% and 2.2%), as was the rate of strokes
affecting multiple territories (0.6% vs 1.5%).
Multivariate analysis revealed that previous cerebro-
vascular accident (CVA; OR, 7.1; 95% CI, 2.2-23.1;
P ¼ .001) and coverage of the LSA (OR, 11.7; 95%
CI, 2.5-54.6; P ¼ .002) were independently associatedwith posterior circulation stroke. Female gender (OR,
3.2; 95% CI, 1.2-8.4; P ¼ .02), requirement for more
than two devices (OR, 2.5; 95% CI, 1-6.7; P ¼ .05),
and renal failure (OR, 2.5; 95% CI, 1-6.8; P ¼ .08)
were independently associated with anterior circulation
stroke.
Fate of patients with neurologic complications. Of
the strokes that occurred <30 days, 11.4% were fatal
(Table III). Of the 39 patients where sufﬁcient data exis-
ted, 30.1% of the nonfatal strokes completely resolved.
Paraparesis was more common than paraplegia in the
perioperative period (64.3% vs 35.7%), and although
limited data were available regarding status at follow-up,
symptoms completely resolved in 60% of all SCI patients.
Fig 1. Graph shows the risk of stroke (in percentages) by territory
in patients undergoing thoracic endovascular aortic repair
(TEVAR). The results are grouped depending on how the left
subclavian artery (LSA) was managed.
Table II. Vascular territory of stroke after thoracic endovascular aortic repair (TEVAR) <30 days
Vascular territorya LSA not covered (n ¼ 537)
LSA covered
PbNot revascularized (n ¼ 318) Revascularized (n ¼ 135)
Posterior 1 (0.1) 12 (3.8) 1 (0.7) <.001
Anterior 5 (0.9) 9 (2.8) 3 (2.2) .105
Multiple 4 (0.7) 2 (0.6) 2 (1.5) .631
Hemorrhage 2 (0.2) 3 (0.9) 0 .354
Unknown 0 3 (0.9) 1 (0.7) .09
LSA, Left subclavian artery.
aData are given as absolute numbers (%).
bP value is for the c2 test.
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survival of patients who did and did not have a stroke,
perioperative stroke and SCI appeared to be a predictor of
a higher mortality rate at follow-up (log-rank, P < .001
and P ¼ .032, respectively; Fig 2).
Effect of LSA management on the incidence of
stroke. The highest rate of 30-day postoperative stroke
was among patients with LSA coverage and no revascu-
larization (9.1%), followed by those with LSA coverage
who underwent revascularization (5.1%), with the lowest
rate in the group that did not require LSA coverage (2.2%;
P < .001; Table IV).
Univariate analysis was conducted for all patients with
data available regarding the management of the LSA. Fe-
male gender, previous CVA, renal insufﬁciency, Ishimaru
zone, coverage of the LSA without revascularization, aortic
pathology, and more than two devices required (a proxy
for length of aortic coverage required), and time of proce-
dure were associated with an increased risk of stroke (P <
.1; Supplementary Table I, online only).
In multivariate analysis, female gender (OR, 2.4; 95%
CI, 1.1-5.0; P ¼ .02), renal insufﬁciency (OR, 2.1; 95%
CI, 1-4.6; P ¼ .07), history of stroke (OR, 2.5; 95% CI,
1.1-5.5; P ¼ .03), requirement for more than two devices
(OR, 2.6: 95% CI, 1.2-5.3; P ¼ .01), and coverage of the
LSA without revascularization (OR, 3.8; 95% CI, 1.8-7.8;
P < .001) were associated with an increased risk of stroke.Effect of LSA management on SCI incidence. SCI
did not differ signiﬁcantly across the three groups. Further
subgroup analysis suggested that revascularizing the LSA
did not appear to alter the rate of stroke in dissection pa-
tients (Table V).
Female gender, history of tobacco use, history of stroke
or CVA, and number of devices used were signiﬁcantly
associated with SCI on univariate analysis (P < .1;
Supplementary Table II, online only). Mode of admission
and pathology did not inﬂuence the likelihood of stroke
or SCI. Multivariate analysis revealed that sex (OR, 1.8;
95% CI, 0.9-3.5; P ¼ .09), previous stroke (OR, 2.1;
95% CI, 0.9-4.6; P ¼ .07), history of tobacco use (OR,
4; 95% CI, 1.4-11.5; P ¼ .011), and more than two devices
used (OR, 2.3 per additional device; 95% CI, 1.2-4.5; P ¼
.018) were independently associated with SCI.
Effect of the timing of LSA revascularization. Data
regarding the timing of LSA revascularization was available
for 97 of 135 patients. Of these 97, 39 (40.2%) underwent
simultaneous revascularization and 58 (58.8%) underwent
prior staged revascularization. The event rates between
these two groups did not differ when univariate analysis
was performed (Supplementary Table III, online only).
DISCUSSION
The principal ﬁnding of the present analysis was an
increased risk of perioperative stroke in patients who
required LSA coverage during TEVAR. This risk was
most pronounced in the patients in whom no LSA revascu-
larization procedure was performed. Subgroup analyses
demonstrated that LSA revascularization was effective in
reducing the incidence of posterior circulation strokes in
patients undergoing elective repair TEVAR for TAA.
Other subgroups of patients at increased risk appeared to
be women, those with renal failure, and those with known
cerebrovascular disease.
Current evidence suggests that stroke during TEVAR
has a multifactorial etiology, with atheroembolization
from the aortic arch and loss of left vertebral artery ﬂow
both contributing. Findings from the present study
demonstrated that the necessity to cover the LSA increased
the incidence of anterior cerebral stroke or multiterritory
infarct. Revascularization of the LSA had no effect on the
incidence of anterior circulation stroke, which was
Table III. Severity, recovery, and rates after early (<30 day) stroke and spinal cord ischemia
Outcomes <30 days Total, No. (%) LSA not covered, No.
LSA covered
Not revascularized, No. Revascularized, No.
Stroke 48 12 29 7
Fatal stroke 5/44 (11.3) 0/11 4/27 1/6
Fully resolved 12/39 (30.1) 4/9 6/25 2/5
Spinal cord ischemia 42 27 13 2
Paraplegia 15/42 (35.7) 10/27 5/13 0/2
Paraparesis 27/42 (64.3) 17/27 8/13 2/2
Resolved 12/20 (60) 9/13 3/7 e
LSA, Left subclavian artery.
Fig 2. Kaplan-Meier curves show the increased risk of death (A) in patients who had a perioperative stroke (log-rank,
P < .001) and (B) in patients who experienced perioperative spinal cord injury (SCI; log-rank, P ¼ .032).
Table IV. Adverse events occurring in each of the three
groups
Eventsa
LSA not covered
(n ¼ 537)
LSA covered
Pb
Not revascularized
(n ¼ 318)
Revascularized
(n ¼ 135)
Death 31 (5.8) 22 (6.9) 10 (7.4) .696
Stroke 12 (2.2) 29 (9.1) 7 (5.1) .000
SCI 27 (5) 13 (4.1) 2 (1.5) .186
LSA, Left subclavian artery; SCI, spinal cord injury.
aData are given as absolute numbers (%).
bThe c2 test was used to compare the frequency of events.
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Volume 60, Number 6 Patterson et al 1495presumed secondary to embolization from the arch. How-
ever, coverage of the LSA without revascularization of the
LSA appeared to increase the incidence of posteriorcirculation stroke, with an OR of 11.7 derived from the
multivariate analysis. This risk was mitigated by revascular-
ization of the LSA. This effect was not seen in the patients
undergoing urgent surgery, presumably because they were
more prone to hypotension and other insults that made
them at a generally higher risk of stroke.
The role of LSA coverage and revascularization on
stroke rate remains controversial. A study of 1189 patients
who underwent TEVAR for various indications suggested
that coverage of the LSA without revascularization did
not increase the risk of stroke, although the numbers of
events were relatively low.14 Despite this, the present ﬁnd-
ings agree closely with other studies that found a positive
association between LSA coverage and stroke rate, particu-
larly in the posterior circulation. Feezor et al15 reported an
increased risk of stroke with LSA coverage in a study of 196
patients undergoing TEVAR, with a reduction in risk from
Table V. Adverse events in each of the three groups divided by pathologya
Eventb Pathology LSA not covered
LSA covered
Not revascularized Revascularized
Stroke TAA 11/394 (2.8) 21/183 (11.5) 4/83 (4.8)
TAD 1/134 (1) 7/119 (5.8) 3/49 (6.1)
SCI TAA 24/394 (6.1) 9/183 (4.9) 2/83 (2.4)
TAD 3/134 (2.2) 4/119 (3.3) 1/49 (2)
LSA, Left subclavian artery; SCI, spinal cord injury; TAA, thoracic aortic aneurysm; TAD, thoracic aortic dissection.
aExcluded were 31 patients with other pathologies (one with a stroke in the covered not revascularized groupdclassed as “other” pathology from the
CAPTIVIA registry) and seven patients because there was no information regarding the management of the LSA.
bData are given as absolute numbers (%).
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tion. Of note, the incidence of posterior circulation stroke
was reduced from 5.5% to 1.2%.
Another series characterized most postoperative strokes
as being embolic in nature, but found endograft coverage
of Ishimaru zone 2 was an independent risk factor for pos-
terior circulation stroke (OR, 6.11; 95% CI, 1.2-32.3; P ¼
.03).16 The authors also reported that previous stroke was
strongly predictive of posterior circulation stroke (OR, 7.5;
95% CI, 1.8-31.8; P ¼ .006), a ﬁnding concordant with
the present study.
Analysis of the American College of Surgeons National
Surgical Quality Improvement Program Participant Use
File demonstrated in a group of 737 patients that coverage
of the LSA was an independent risk factor for stroke (OR,
2.17; 95% CI, 1.13-4.14), as was placement of a proximal
aortic cuff (OR, 2.58; 95% CI, 1.30-5.16). That severe
atheroma in the aortic arch can lead to up to a ﬁvefold in-
crease in stroke has also been observed.17
The beneﬁcial effect of LSA revascularization noted in
patients with aneurysmal disease in the present study may
reﬂect the absolute differences between stroke incidence
in patients with TAA and thoracic aortic dissection.13 Pa-
tients with TAA often have a greater burden of macrovas-
cular and microvascular atherosclerotic disease, which may
alter the ability of these patients to withstand loss of one
feeding vessel to the circle of Willis.
The present analysis found a nonsigniﬁcant reduced
rate of SCI amongst patients who underwent LSA revas-
cularization compared with those who did not (4% vs
1.4%). Of note, coverage of the LSA, regardless of subse-
quent management, did not seem to increase the risk (5%
vs 3%, P ¼ .16), which is at odds with some previous
studies.6,18 A report from the European Collaborators
on Stent-Graft Techniques for Abdominal Aortic Aneu-
rysm Repair (EUROSTAR) registry of 606 patients re-
ported an SCI rate of 2.5% and found that coverage of
the LSA without revascularization was an independent
risk factor (OR, 3.9; 95% CI, 1.17-13.3). In the EURO-
STAR analysis, length of aortic coverage was also impor-
tant in the development of this complication, and
patients with three or more stent grafts had a higher inci-
dence of SCI (OR, 3.49; CI, 1.04-11.7), which is similar
to the present study.19 Other recent studies withcomparative numbers of patients have shown that SCI
was associated with renal failure, length of coverage, and
emergency operations.14,20 The ﬁnding that mortality
was markedly increased in patients sustaining neurologic
complications after surgery has been described previ-
ously16 and is not surprising.
The limitations of this analysis include the number of
patients in each group and subgroup, which limited the po-
wer of the study to draw ﬁrm conclusions and make deﬁn-
itive recommendations for clinical practice. Some
important ﬁelds (eg, use of spinal drains) were not com-
plete enough in all of the studies to include in our analysis.
There was no way of gaining access to all of the preopera-
tive investigations for each patient, meaning no reliable
data for features such as burden of atherosclerosis or the
integrity of the circle of Willis were available for analysis.
Data describing the revascularization procedure itself
were limited, so there was no way of telling what propor-
tion of patients did not undergo TEVAR after a revascular-
ization procedure on the LSA.
It is important to recognize that most of these patients
were part of sponsored trials, of which most had speciﬁc
exclusion criteria. The rates of stroke and paraplegia were
similar to other device speciﬁc studies, such as those for
the TAG (W. L. Gore and Associates, Flagstaff, Ariz) and
the Zenith TX2 (Cook Medical, Indianapolis, Ind) devices.
Centers involved in these studies were selected because the
clinicians involved had sufﬁcient experience in TEVAR to
safely implant devices. This may mean that the rates of
adverse events reported in this study may be slightly
more favorable than in global practice, and some caution
should be applied to generalizing them.
CONCLUSIONS
The present study found that coverage of the LSA was
associated with an increased risk of stroke in patients un-
dergoing TEVAR. This effect was most marked in those
who were treated electively for a TAA compared with a
Stanford type B dissection. Multivariate analysis suggested
that covering the LSA without revascularization was the
only modiﬁable risk factor for stroke. Coverage of the
LSA presumably led to a greater risk of posterior cerebral
artery territory stroke due to cessation of antegrade ﬂow
in the left vertebral artery. The requirement for extensive
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 6 Patterson et al 1497aortic coverage and a history of previous cerebrovascular
disease was predictive of stroke. The occurrence of peripro-
cedural neurologic complications during TEVAR signiﬁ-
cantly increased the risk of all-cause mortality at midterm
follow-up, emphasizing the need to develop preventative
strategies. Revascularization of the LSA should be consid-
ered in all patients undergoing elective TEVAR for TAA
and on a case-by-case basis in patients undergoing urgent
surgery or surgery for dissection.
We acknowledge Debra Shaver and Lois Fisher of
Medtronic for providing the registry data and assisting
with the study.
AUTHOR CONTRIBUTIONS
Conception and design: BP, MT, PH
Analysis and interpretation: BP, PH, MT
Data collection: MT, RH, CN, RF
Writing the article: BP, PH, RH
Critical revision of the article: CN, RH, MT
Final approval of the article: MT
Statistical analysis: BP, PH
Obtained funding: Not applicable
Overall responsibility: MT
REFERENCES
1. Scali ST, Goodney PP, Walsh DB, Travis LL, Nolan BW,
Goodman DC, et al. National trends and regional variation of open and
endovascular repair of thoracic and thoracoabdominal aneurysms in
contemporary practice. J Vasc Surg 2011;53:1499-505.
2. Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC,
Cronenwett JL, et al. Survival after open versus endovascular thoracic
aortic aneurysm repair in an observational study of the Medicare pop-
ulation. Circulation 2011;124:2661-9.
3. Görich J, Asquan Y, Seifarth H, Krämer S, Kapfer X, Orend KH, et al.
Initial experience with intentional stent-graft coverage of the subclavian
artery during endovascular thoracic aortic repairs. J Endovasc Ther
2002;9(Suppl 2):II39-43.
4. Tiesenhausen KK, Hausegger KA, Oberwalder PP, Mahla EE,
Tomka MM, Allmayer TT, et al. Left subclavian artery management in
endovascular repair of thoracic aortic aneurysms and aortic dissections.
J Card Surg 2003;18:429-35.
5. Chung J, Kasirajan K, Veeraswamy RK, Dodson TF, Salam AA,
Chaikof EL, et al. Left subclavian artery coverage during thoracic
endovascular aortic repair and risk of perioperative stroke or death.
J Vasc Surg 2011;54:979-84.
6. Weigang EE, Luehr MM, Harloff AA, Euringer WW, Etz CD,
Szabó GG, et al. Incidence of neurological complications following
overstenting of the left subclavian artery. Eur J Cardiothorac Surg
2007;31:628-36.
7. Matsumura JS, Lee WA, Mitchell RS, Farber MA, Murad MH,
Lumsden AB, et al. The Society for Vascular Surgery practiceguidelines: management of the left subclavian artery with thoracic
endovascular aortic repair. J Vasc Surg 2009;50:1155-8.
8. Fairman RM, Criado FJ, Farber MA, Kwolek CJ, Mehta M, White RA,
et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent
Graft System: the VALOR Trial. J Vasc Surg 2008;48:546-54.e2.
9. Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R,
Rehders TC, et al. Randomized comparison of strategies for type B
aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissec-
tion (INSTEAD) Trial. Circulation 2009;120:2519-28.
10. Fairman RM, Tuchek JM, Lee WA, Kasirajan K, White R, Mehta M,
et al. Pivotal results for the Medtronic Valiant Thoracic Stent Graft
System in the VALOR II trial. J Vasc Surg 2012;56:1222-31.e1.
11. Heijman RH, Thompson MM, Fattori R, Goktay Y, Teebken OE,
Orend KH. Valiant thoracic stent-graft deployed with the new Captivia
delivery system: procedural and 30-day results of the Valiant Captivia
Registry. J Endovasc Ther 2012;19:213-25.
12. VIRTUE Investigators. The VIRTUE registry of type B thoracic
dissectionsdstudy design and early results. Eur J Vasc Endovasc Surg
2011;41:159-66.
13. Patterson B, Holt P, Nienaber C, Cambria R, Fairman R,
Thompson M. Aortic pathology determines midterm outcome after
endovascular repair of the thoracic aorta: report from the Medtronic
Thoracic Endovascular Registry (MOTHER) database. Circulation
2013;127:24-32.
14. Maldonado TS, Dexter D, Rockman CB, Veith FJ, Garg K, Arko F,
et al. Left subclavian artery coverage during thoracic endovascular
aortic aneurysm repair does not mandate revascularization. J Vasc Surg
2013;57:116-24.
15. Feezor RJ, Martin TD, Hess PJ, Klodell CT, Beaver TM, Huber TS,
et al. Risk factors for perioperative stroke during thoracic endovascular
aortic repairs (TEVAR). J Endovasc Surg 2007;14:568-73.
16. Ullery BW, McGarvey M, Cheung AT, Fairman RM, Jackson BM,
Woo EY, et al. Vascular distribution of stroke and its relationship to
perioperative mortality and neurologic outcome after thoracic endo-
vascular aortic repair. J Vasc Surg 2012;56:1510-7.
17. Kotelis D, Bischoff MS, Jobst B, Tengg-Kobligk von H, Hinz U,
Geisbüsch P, et al. Morphological risk factors of stroke during
thoracic endovascular aortic repair. Langenbecks Arch Surg 2012;397:
1267-73.
18. Cooper DG, Walsh SR, Sadat U, Noorani A, Hayes PD, Boyle JR.
Neurological complications after left subclavian artery coverage during
thoracic endovascular aortic repair: a systematic review and meta-
analysis. J Vasc Surg 2009;49:1594-601.
19. Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, et al.
Neurologic complications associated with endovascular repair of
thoracic aortic pathology: incidence and risk factors. A study from
the European Collaborators on Stent/Graft Techniques for Aortic
Aneurysm Repair (EUROSTAR) Registry. J Vasc Surg 2007;46:
1103-10.e2.
20. Ullery BW, Cheung AT, Fairman RM, Jackson BM, Woo EY,
Bavaria J, et al. Risk factors, outcomes, and clinical manifestations of
spinal cord ischemia following thoracic endovascular aortic repair.
J Vasc Surg 2011;54:677-84.
Submitted May 19, 2014; accepted Aug 27, 2014.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSIONDr Jon Matsumura (Madison, Wisc). Can you tell us how the
left subclavian coverage was ascertained? Speciﬁcally, was it from a
case report form or was it a core lab review of images? How did
you treat classiﬁcation for partial coverage of the left subclavian
or coverage with a bare-metal spring?
Dr Benjamin O. Patterson. I think that as you’d be aware
from these sort of registries that the data are collected in different
formats depending on which registry it is. Most of them actuallyhad an entry for management of the left subclavian artery, and
we derived it from there. Otherwise, we derived it from looking
at which revascularization procedures were performed and what
the zone of coverage was. Where it was partially covered, we clas-
siﬁed these as covered. In terms of coverage with the bare metal
spring, we did not have that data speciﬁcally.
Dr Marc Schermerhorn (Boston, Mass). Are you sure you
haven’t missed any patients who may have had a revascularization
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1498 Patterson et al December 2014procedure but then either died or had a stroke and then they never
had a stent graft put in? The stroke and death rate with revascular-
ization may be higher than your current estimate.
Dr Patterson.We do not have any data because they were all
patients that had a device inserted. And for our database then, I
identiﬁed the patients based on their stenting procedures, so I
can’t give any data regarding the rates of adverse events following
the revascularization itself.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I noticed
that in your data you have got both the registry data as well as
the data from St George’s. I noticed some of your coauthors are
from Philadelphia. I wonder why you didn’t have any data from
them?
And secondly, this is all registry data, or did these people have
to meet inclusion criteria to be in the registry? We all understand
the difference between real world applicability of stent grafts and
that data which are derived from clinical trials. In many clinical tri-
als, the difﬁcult anatomy is all selected out, and in fact, registry data
may give a better set of data than what happens in the real world.
So can you comment, on the source of this data? Was it consecu-
tive patients that were enrolled in the registry or did they have to
meet certain clinical inclusion criteria? And were there differences
between those patients and the St George’s group, which may
reﬂect nonclinical trial enrollment?
Dr Patterson. I think that there are differences between the
various registries. For example, the high risk of the VALOR study
included patients with lots of comorbidities that were not ﬁt foropen repair. In general, the St George’s cohort had more comor-
bidities and there were more urgent cases than in the other regis-
tries. The set which most mirrored ours in terms of the patient
demographics was the Captivia set, which has all indications. We
basically took all of the patients that were involved in the registries
and pooled them. We did not apply any inclusion or exclusion
criteria to them per se.
Dr Sateesh Babu (Hawthorne, NY). What is the working hy-
pothesis for the stroke in these patients? Unless one can postulate
the vertebrobasilar territory ischemic events, it is difﬁcult to explain
strokes in these patients.
Dr Patterson.Well, it is difﬁcult to say. I think the ﬁrst thing
to point out is just looking at our regression analysis makes the
relationship quite clear. But we hypothesize that it is probably to
do with interruption of the collateral supply of the circle of Willis.
If one looks at the data from the asymptomatic carotid surgery
trial, there is actually a protective effect on contralateral stroke in
the group that underwent surgery when you compare it with the
controls. There was a three times higher rate of contralateral stroke
in that group adding weight to the collateralization theory.
Dr Robert Zwolak (Lebanon, NH). Is there any information
in the databases about the timing of the subclavian revasculariza-
tion with regard to the aortic repair?
Dr Patterson. There is some, but it was too incomplete really
to incorporate in our analysis. But there is some. We could do a
subgroup analysis, but there is not a great deal of that information
available.
Supplementary Table I (online only). Association of
univariate analysis of preoperative risk factors with the
occurrence of stroke #30 days
Variables OR 95% CI Pa
Age .420b
Glasgow Aneurysm Score .056b
Female gender 1.698 0.947-3.042 .085
Previous CVA 2.688 1.381-5.232 .006
Age >75 years 0.887 0.469-1.677 .874
Renal insufﬁciency 2.167 1.135-4.136 .026
Previous myocardial infarction 1.603 0.795-3.232 .221
Hypertension 0.754 0.337-1.508 .445
Coronary artery disease 1.291 0.706-2.359 .431
Tobacco use 0.847 4.65-1.544 .639
Respiratory disease 1.151 0.606-2.187 .736
Arrhythmia 0.597 0.246-1.452 .327
Hyperlipidemia 0.703 0.371-1.329 .336
Diabetes 1.658 0.806-3.410 .197
Previous aortic surgery 1.9 0.625-6.21 .35
Mode of admission 1.258 0.615-2.576 .558
Pathology
TAA vs acute chronic TAD e e .084c
TAA vs TAD 1.405 0.722-2.735 .401
ASA e e .748c
Ishimaru zone e e .005c
>2 devices used 2.541 1.289-5.01 .007b
Time of procedure .001c
Coverage of the LSA 3.27 1.71-3.23 <.001
Without revascularization 4.33 2.09-9.13 <.001
ASA, American Society of Anesthesiologists; CI, conﬁdence interval; CVA,
cerebrovascular accident; LSA, left subclavian artery; OR, odds ratio; TAA,
thoracic aortic aneurysm; TAD, thoracic aortic dissection.
aThe Fisher exact test was used, except as indicated.
bCalculated by t-test.
cCalculated by c2 due to contingency tables >2  2.
Supplementary Table II (online only). Shows the
association of univariate analysis of preoperative risk
factors with the occurrence of spinal cord injury (SCI)
#30 days
Variables OR 95% CI Pa
Age .451b
Glasgow Aneurysm Score .234b
Female gender 2.228 1.198-4.141 .012
Previous CVA 2.212 1.059-4.617 .054
Age over 75 0.760 0.377-1.533 .501
Renal insufﬁciency 0.687 0.266-1.779 .526
Previous myocardial infarction 0.539 0.189-1.537 .286
Hypertension 1.669 0.646-4.314 .410
Coronary artery disease 1.217 0.637-2.326 .613
Tobacco use 2.574 1.128-5.873 .019
Respiratory disease 1.588 0.828-3.048 .207
Arrhythmia 0.442 0.147-1.213 .145
Hyperlipidemia 1.199 0.618-2.324 .617
Diabetes 1.771 0.826-3.797 .164
Previous aortic surgery 1.192 0.912-2.454 .56
Mode of admission 0.780 0.324-1.881 .682
Pathology
TAA vs acute chronic dissection e .175c
TAA vs TAD 1.932 0.905-4.123 .090
ASA e .479c
Ishimaru zone e .899c
>3 devices used 2.627 1.364-5.23 .005b
Time of procedure .003c
Coverage of the LSA 0.78 0.41-1.46 .53
Without revascularization 0.77 0.37-1.58 .51
ASA, American Society of Anesthesiologists; CI, conﬁdence interval; CVA,
cerebrovascular accident; LSA, left subclavian artery; OR, odds ratio; TAA,
thoracic aortic aneurysm; TAD, thoracic aortic dissection.
aFisher exact test was used for the analysis except as indicated.
bCalculated by t-test.
cCalculated by c2 was used due to contingency tables >2  2.
Supplementary Table III (online only). Rates of
perioperative adverse events in patients undergoing
staged revascularization of the left subclavian artery
(LSA) vs single procedures
Events Staged (n ¼ 58), No. (%) Single (n ¼ 39), No. (%) P
30-day
Death 3 (5.2) 1 (2.6) .646
Stroke 2 (3.4) 4 (10.3) .216
SCI 0 0 e
SCI, Spinal cord injury.
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